Credit Suisse Ag Humanigen, Inc Transaction History

Credit Suisse Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.76 - $3.33 $43,132 - $81,608	-24,507 Reduced 99.89%	26 $0
Q1 2022 May 16, 2022	BUY	$1.81 - $3.97 $3,887 - $8,527	2,148 Added 9.6%	24,533 $73,000
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $12,206 - $27,413	3,335 Added 17.51%	22,385 $84,000
Q3 2021 Nov 12, 2021	BUY	$5.93 - $17.83 $13,283 - $39,939	2,240 Added 13.33%	19,050 $112,000
Q2 2021 Aug 16, 2021	BUY	$13.54 - $22.74 $54,796 - $92,028	4,047 Added 31.71%	16,810 $292,000
Q1 2021 May 14, 2021	BUY	$12.91 - $23.83 $164,770 - $304,142	12,763 New	12,763 $244,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.